Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Department of Pharmacy, Xuzhou Oriental Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
J Diabetes Res. 2022 Jul 20;2022:5854200. doi: 10.1155/2022/5854200. eCollection 2022.
The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme.
8371 T2DM patients from four dapagliflozin studies and two canagliflozin studies were collected for analyzing with nonlinear mixed effect model (NONMEM). The change rates of UACR from baseline were intended to be evaluation indicators.
In the present study, there was no significant difference in the effects on UACR using dapagliflozin or canagliflozin treatment in T2DM patients. The maximal effect ( ) and the treatment duration of reaching half of (ET) from SGLT-2 inhibitors on UACR in T2DM patients were -19.2% and 0.448 weeks, respectively. Further, the treatment duration to reach 25%, 50%, 75%, and 80% was 0.150 weeks, 0.448 weeks, 1.344 weeks, and 1.792 weeks, respectively. Namely, for achieving the plateau period (80% of ) of SGLT-2 inhibitors on UACR in T2DM patients, 10 mg/day dapagliflozin (or 100 mg/day canagliflozin) should be taken for at least 1.792 weeks.
To our knowledge, the present study explored the effects of SGLT-2 inhibitors on UACR in T2DM patients, meanwhile, recommended appropriate medication care scheme for the first time.
本研究旨在探讨钠-葡萄糖共转运蛋白-2（SGLT-2）抑制剂对 2 型糖尿病（T2DM）患者尿白蛋白与肌酐比值（UACR）的影响，并推荐合适的药物治疗方案。
收集了来自 4 项达格列净研究和 2 项卡格列净研究的 8371 例 T2DM 患者数据，采用非线性混合效应模型（NONMEM）进行分析。UACR 自基线的变化率被用作评估指标。
在本研究中，T2DM 患者使用达格列净或卡格列净治疗对 UACR 的影响无显著差异。SGLT-2 抑制剂对 UACR 的最大效应（ ）和达到 一半所需的治疗时间（ET）分别为-19.2%和 0.448 周。此外，达到 25%、50%、75%和 80% 所需的治疗时间分别为 0.150 周、0.448 周、1.344 周和 1.792 周。即，要达到 SGLT-2 抑制剂对 T2DM 患者 UACR 的平台期（80% ），需要至少服用 10 mg/天达格列净（或 100 mg/天卡格列净）1.792 周。
据我们所知，本研究首次探讨了 SGLT-2 抑制剂对 T2DM 患者 UACR 的影响，并推荐了合适的药物治疗方案。
